.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
QuintilesIMS
US Department of Justice
Medtronic
UBS
Fish and Richardson
Teva
Citi
Farmers Insurance
Julphar

Generated: September 19, 2017

DrugPatentWatch Database Preview

MEGACE Drug Profile

« Back to Dashboard

What is the patent landscape for Megace, and when can generic versions of Megace launch?

Megace is a drug marketed by Bristol Myers Squibb and Endo Pharms Inc and is included in three NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MEGACE is megestrol acetate. There are eighteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

Summary for Tradename: MEGACE

Patents:0
Applicants:2
NDAs:3
Suppliers / Packagers: see list1
Bulk Api Vendors: see list71
Clinical Trials: see list20
Patent Applications: see list6,732
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEGACE at DailyMed

Pharmacology for Tradename: MEGACE

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
MEGACE
megestrol acetate
SUSPENSION;ORAL020264-001Sep 10, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
MEGACE
megestrol acetate
TABLET;ORAL016979-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
MEGACE
megestrol acetate
TABLET;ORAL016979-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MEGACE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
MEGACE
megestrol acetate
SUSPENSION;ORAL020264-001Sep 10, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MEGACE

Drugname Dosage Strength RLD Submissiondate
megestrol acetateOral Suspension125 mg/mLMegace ES
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Teva
Novartis
Mallinckrodt
US Army
Chubb
McKesson
Dow
Cerilliant
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot